Abstract
We conducted a phase I study using midostaurin (25 or 50 mg orally twice daily), all-trans retinoic acid (ATRA) and CLAG chemotherapy to target multiple pathways in relapsed/refractory AML. 10 patients received the combination and no dose-limiting toxicities were observed. Two patients (22 %) achieved complete remission and 1 patient (11 %) achieved complete remission with incomplete count recovery. Pharmacokinetic data showed that the 25 mg dosing of midostaurin achieved therapeutic levels with no significant interaction between midostaurin and ATRA. With evidence of activity of ATRA in NPM1-mutated AML and midostaurin in FLT3-ITD AML, this combination warrants further investigation.
Original language | English |
---|---|
Pages (from-to) | 272-278 |
Number of pages | 7 |
Journal | International Journal of Hematology |
Volume | 99 |
Issue number | 3 |
DOIs | |
State | Published - Mar 2014 |
Keywords
- AML
- ATRA
- CLAG
- Midostaurin
- Phase I
- Targeted therapy